Although the mechanisms of synergy appear to differ based on cancer model, sensitivity, intrinsic versus acquired resistance and different indications, we equally observe the combination of mutant-selective KRAS inhibitors with IAG933 ultimately promoting sustained antiproliferative and proapoptotic effects. This evidence concerns the gene KRAS and cancer.